EP0946164A4 - Antagonistes de l'integrine - Google Patents
Antagonistes de l'integrineInfo
- Publication number
- EP0946164A4 EP0946164A4 EP97913775A EP97913775A EP0946164A4 EP 0946164 A4 EP0946164 A4 EP 0946164A4 EP 97913775 A EP97913775 A EP 97913775A EP 97913775 A EP97913775 A EP 97913775A EP 0946164 A4 EP0946164 A4 EP 0946164A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- integrin antagonists
- integrin
- antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2922396P | 1996-10-30 | 1996-10-30 | |
US29223P | 1996-10-30 | ||
GBGB9626308.2A GB9626308D0 (en) | 1996-12-18 | 1996-12-18 | av›3 antagonists |
GB9626308 | 1996-12-18 | ||
PCT/US1997/019349 WO1998018461A1 (fr) | 1996-10-30 | 1997-10-27 | Antagonistes de l'integrine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0946164A1 EP0946164A1 (fr) | 1999-10-06 |
EP0946164A4 true EP0946164A4 (fr) | 2000-08-23 |
Family
ID=26310673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97913775A Withdrawn EP0946164A4 (fr) | 1996-10-30 | 1997-10-27 | Antagonistes de l'integrine |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0946164A4 (fr) |
JP (1) | JP2001504456A (fr) |
AU (1) | AU717283B2 (fr) |
WO (1) | WO1998018461A1 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
US6066648A (en) | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
US6211191B1 (en) | 1997-12-17 | 2001-04-03 | Merck & Co., Inc. | Integrin receptor antagonists |
CA2336703A1 (fr) * | 1998-07-10 | 2000-01-20 | The University Of Sydney | Traitements prophylactiques de la neoformation de vaisseaux sanguins dans la degenerescence maculaire |
JP2002521450A (ja) * | 1998-07-29 | 2002-07-16 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体アンタゴニスト |
AU748621B2 (en) * | 1998-08-13 | 2002-06-06 | Merck & Co., Inc. | Integrin receptor antagonists |
FR2786182B1 (fr) * | 1998-11-24 | 2001-01-12 | Hoechst Marion Roussel Inc | Nouveaux derives d'acylguanidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
US6677360B2 (en) | 1998-12-16 | 2004-01-13 | Bayer Aktiengesellschaft | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
US6291503B1 (en) | 1999-01-15 | 2001-09-18 | Bayer Aktiengesellschaft | β-phenylalanine derivatives as integrin antagonists |
BR0009739A (pt) | 1999-04-13 | 2002-04-09 | Basf Ag | Composto, medicamento, preparação farmacêutica, e, usos de um elemento estrutural, de um composto e de uma preparação farmacêutica |
CA2373937A1 (fr) | 1999-06-02 | 2000-12-07 | Merck & Co., Inc. | Antagonistes du recepteur de l'alpha v integrine |
WO2000075129A1 (fr) * | 1999-06-07 | 2000-12-14 | Shire Biochem Inc. | Inhibiteurs d'integrine thiophene |
EP1065208A1 (fr) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Dérivés substitués de la purine inhibiteurs de l'adhésion cellulaire |
EP1065207A1 (fr) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Dérivées de la naphthyridine, procédés pour leur preparation, leur utilisation, et compositions pharmaceutique les contenant |
DE19939981A1 (de) * | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Neue Inhibitoren des Integrins alphavß3 |
US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
CA2386030A1 (fr) * | 1999-10-04 | 2001-04-12 | Merck & Co., Inc. | Antagonistes des recepteurs d'integrine |
DE10039998A1 (de) * | 2000-08-11 | 2002-02-21 | Basf Ag | Neue substituierte Diareno-azepin-Derivate als Integrin Liganden |
WO2001027082A1 (fr) * | 1999-10-08 | 2001-04-19 | Meiji Seika Kaisha, Ltd. | DERIVES DE 3-AMINOPIPERIDINE UTILISES COMME ANTAGONISTES DE L'INTEGRINE αvβ3 |
US6849639B2 (en) | 1999-12-14 | 2005-02-01 | Amgen Inc. | Integrin inhibitors and their methods of use |
WO2001053297A1 (fr) * | 2000-01-20 | 2001-07-26 | Merck & Co., Inc. | Antagonistes du recepteur de l'integrine alpha v |
US6545029B2 (en) | 2000-06-12 | 2003-04-08 | Bayer Aktiengesellschaft | Phenylserine derivatives as integrin antagonists |
ATE530183T1 (de) * | 2001-01-29 | 2011-11-15 | Ortho Mcneil Pharm Inc | Substituierte indole und ihre verwendung als integrin-antagonisten |
ATE468325T1 (de) | 2001-03-19 | 2010-06-15 | Dainippon Sumitomo Pharma Co | Arylsubstituierte alicyclische verbindung und diese enthaltende medizinische zusammensetzung |
RU2316337C2 (ru) | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
JP2006516144A (ja) | 2002-12-20 | 2006-06-22 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニスト誘導体としてのチアゾール化合物 |
CA2637387A1 (fr) | 2006-01-18 | 2007-07-26 | Simon Goodman | Traitement specifique utilisant des ligands de l'integrine destine a traiter un cancer |
EA017864B1 (ru) | 2007-01-18 | 2013-03-29 | Мерк Патент Гмбх | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака |
CN102448497A (zh) | 2009-05-25 | 2012-05-09 | 默克专利有限公司 | 在癌症治疗中的西仑吉肽的持续给药 |
ES2957460T3 (es) | 2013-09-24 | 2024-01-19 | Fujifilm Corp | Composición farmacéutica de un compuesto que contiene nitrógeno o una sal del mismo, o complejo de metal de los mismos |
ES2968371T3 (es) | 2013-10-10 | 2024-05-09 | Eastern Virginia Medical School | Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa |
AU2015265571A1 (en) | 2014-05-30 | 2016-11-17 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
WO2023275715A1 (fr) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025892A1 (fr) * | 1996-12-09 | 1998-06-18 | Eli Lilly And Company | Antagonistes de l'integrine |
WO1998044797A1 (fr) * | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | Procede de traitement du cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5416099A (en) * | 1991-10-29 | 1995-05-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
CA2190870A1 (fr) * | 1994-05-27 | 1995-12-07 | George D. Hartman | Composes inhibiteurs de la resorption osseuse induite par osteoclaste |
-
1997
- 1997-10-27 JP JP52063998A patent/JP2001504456A/ja active Pending
- 1997-10-27 EP EP97913775A patent/EP0946164A4/fr not_active Withdrawn
- 1997-10-27 WO PCT/US1997/019349 patent/WO1998018461A1/fr not_active Application Discontinuation
- 1997-10-27 AU AU50884/98A patent/AU717283B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998025892A1 (fr) * | 1996-12-09 | 1998-06-18 | Eli Lilly And Company | Antagonistes de l'integrine |
WO1998044797A1 (fr) * | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | Procede de traitement du cancer |
Non-Patent Citations (2)
Title |
---|
EGBERTSON M S ET AL: "Nonpeptide GPIIB/IIIA inhibitors. 10. centrally constrained alpha-sulfonamides are potent inhibitors of platelet aggregation", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 6, no. 21, 5 November 1996 (1996-11-05), pages 2519 - 2524, XP004135906, ISSN: 0960-894X * |
See also references of WO9818461A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP0946164A1 (fr) | 1999-10-06 |
AU717283B2 (en) | 2000-03-23 |
AU5088498A (en) | 1998-05-22 |
JP2001504456A (ja) | 2001-04-03 |
WO1998018461A1 (fr) | 1998-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0934305A4 (fr) | Antagonistes de l'integrine | |
EP0946164A4 (fr) | Antagonistes de l'integrine | |
EP1007026A4 (fr) | Antagonistes d'integrine | |
EP1047425A4 (fr) | Antagonistes du recepteur de l'integrine | |
AU3213799A (en) | Integrin antagonists | |
EP0912175A4 (fr) | Antagonistes du recepteur de fibrinogene | |
EP1100506A4 (fr) | Antagonistes des recepteurs de l'integrine | |
HU9603525D0 (en) | Vironectin receptor antagonists | |
HU9603082D0 (en) | Neurokinine (tachykinine) antagonists | |
EP1105389A4 (fr) | Antagonistes de recepteurs d'integrine | |
PL331534A1 (en) | Muscarinic antagonists | |
EP1007051A4 (fr) | Antagonistes du recepteur de l'integrine | |
EP0880511A4 (fr) | Antagonistes du recepteur integrine | |
EP0913191A4 (fr) | Microemulsion | |
EP0885205A4 (fr) | Antagonistes des recepteurs de fibrinogenes | |
HU9601176D0 (en) | Adhesion-receptor antagonists | |
EP0885213A4 (fr) | Antagonistes du recepteur du fibrinogene | |
IL134175A0 (en) | Endothelin antagonists | |
EP1027337A4 (fr) | Antagonistes des recepteurs d'integrines | |
HU9503191D0 (en) | Adhesion-receptor antagonists | |
ZA98256B (en) | Tachykinin antagonists | |
GB9820014D0 (en) | Receptor antagonists and uses thereof | |
ZA985209B (en) | Endothelin antagonists | |
GB9724656D0 (en) | Local oscillator arrangement | |
GB9616786D0 (en) | Catch |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990531 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07D 471/04 A, 7A 61K 31/435 B, 7C 07D 239/42 B, 7C 07D 213/74 B, 7C 07D 239/14 B, 7A 61K 31/44 B, 7A 61K 31/505 B |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000711 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20020528 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040301 |